Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review

BACKGROUND: Cardiovascular outcome trials have demonstrated cardiovascular safety of glimepiride (a sulfonylureas) against dipeptidyl peptidase-4 inhibitor linagliptin. Gliclazide (another newer sulfonylureas) has shown similar glycemic efficacy and 50% decreased risk of hypoglycemia compared to gli...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohan, Viswanathan, Wangnoo, Subhash, Das, Sambit, Dhediya, Rajnish, Gaurav, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Systematic Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791565/
https://www.ncbi.nlm.nih.gov/pubmed/36578872
http://dx.doi.org/10.4239/wjd.v13.i12.1168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791565/
https://www.ncbi.nlm.nih.gov/pubmed/36578872
http://dx.doi.org/10.4239/wjd.v13.i12.1168

Ejemplares similares